title: Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report.
abstract: Type I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a course of treatment should only be due to severe patient intolerance. We report the successful use of intravenous etoposide phosphate as a substitute drug in a patient with a yolk sac tumor who manifested a Type I hypersensitivity to intravenous etoposide. The patient ultimately completed all 4 cycles of bleomycin, etoposide, cisplatin (BEP) using etoposide phosphate as a substitute drug.
authors.affiliation: MacDonald Women's Hospital, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
authors.forename: David
authors.initials: D
authors.lastname: Starks
authors.forename: Deborah
authors.initials: D
authors.lastname: Prinz
authors.forename: Amy
authors.initials: A
authors.lastname: Armstrong
authors.forename: Lindsay
authors.initials: L
authors.lastname: Means
authors.forename: Steven
authors.initials: S
authors.lastname: Waggoner
authors.forename: Robert
authors.initials: R
authors.lastname: Debernardo